OPEN END TURBO SHORT - INCYTE CO. Share Price

DE000MB6RZS2

Market Closed - Börse Stuttgart 01:26:44 18/05/2024 am IST
1.24 ^EUR	-2.36%

Current month	-29.14%
1 month	-24.39%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM	15/05
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress	15/05	BU
Equities Close Mixed as Markets Weigh Consumer Inflation Survey	14/05	MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey	14/05	MT

More news

Quotes 5-day view

Date	Price	Change
17/24/17	1.24	-2.36%
16/24/16	1.27	+2.42%
15/24/15	1.24	-0.80%
14/24/14	1.25	+3.31%
13/24/13	1.21	-25.31%

Delayed Quote Börse Stuttgart

Last update May 18, 2024 at 01:26 am IST

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	PUT
Underlying	INCYTE CORPORATION
Issuer	Morgan Stanley
WKN	MB6RZS
ISIN	DE000MB6RZS2
Date issued	31/05/2023
Strike	70.53 $
Maturity	Unlimited
Parity	10 : 1
Emission price	0.71 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.83 €
Lowest since issue	0.35 €

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.1 USD

Average target price

73.35 USD

Spread / Average Target

+28.46%

Consensus